Previous evidence (mainly derived from surgical series and/or in non-erlotinib treated patients) suggests a potential role of pERK and pAKT in pancreatic cancer biology and both markers additionally may represent a more appropriate way to assess EGFR pathway activation compared to single upstream markers like EGFR itself[14–17]. This evidence concerns the gene EIF2AK3 and familial pancreatic carcinoma.